
Should We Be Worried About Bird Flu? Public Health Experts Say Yes
You don't need me to tell you Covid-19 changed the world. While the pandemic did help expose structural inequalities and disparities, especially in the food system, the loss of life and livelihood has been one of the greatest tragedies of our lifetimes.
I'm bringing this up because, if we ignore the lessons we should've learned from this pandemic, future disease outbreaks will be much, much worse. And I'm deeply concerned that, when it comes to avian flu—a.k.a. Highly Pathogenic Avian Influenza A (HPAI) H5N1—we're on a dangerously wrong path.
This virus typically affects birds, including poultry, and there's a current outbreak that has affected close to 150 million birds and devastated farms since 2022. Also concerningly, scientists have detected the virus in mammals in recent years—including dairy cows and humans—and learned it can spread between mammals, which significantly raises the outbreak risk. And since 2024, 102 cases of avian flu and 10 deaths have been reported in humans globally, a potentially staggering fatality rate.
Many of these global cases over the past year and a half—about 70—have been in the U.S., which means the world's eyes are watching. And so far, this country's response has been nearly the polar opposite of what scientists call for, which puts everyone around the world in greater danger.
'We have so many tools, but they're not being used optimally—and they're not being used optimally by choice,' says Dr. Amesh Adalja, a Senior Scholar at the Johns Hopkins Center for Health Security and an expert in global public health. 'We can change the trajectory of this if we actually take those best practices, take those tools, and use them optimally.'
To be perfectly clear, there is currently no known person-to-person spread of avian flu and experts say the current public health risk is low, per the U.S. Centers for Disease Control and Prevention.
What this means, though, is that the time to prevent and contain this virus is right now.
There's a very real possibility that avian flu could pose a greater threat in the future, and we can't be caught unprepared. The correct course of action involves vaccination, investments in public health, and global collaboration—all of which appear to be under threat given recent U.S. policy developments.
Secretary of Agriculture Brooke Rollins' original plan to combat avian flu included US$100 million in research and vaccine development. But shortly after announcing it, she reversed course and told right-wing site Breitbart that vaccines were 'off the table.' Meanwhile, in May, the Trump-Vance Administration cancelled a massive contract with Moderna to develop a vaccination for humans against bird flu, and this month, Health Secretary Robert F. Kennedy Jr. fired all 17 members of the advisory committee that helps develop vaccine policy and recommendations for the CDC.
'I'm optimistic that they will continue to support the development of these vaccines. It would be a crime right now to stop it,' said Scott Hensley, a virologist at the University of Pennsylvania in Philadelphia who worked on an avian flu vaccine for cattle.
Vaccines save lives. Just last month, early results from that experimental bird flu vaccine for cattle came back promising. The U.S. Department of Agriculture conditionally approved a vaccine for poultry this spring, and some countries, like China and France, already vaccinate poultry against H5N1. Even in humans, Finland last year became the first country to roll out bird flu vaccines among its population.
Alternative courses of action, rather than vaccines, are devastating: In March, Kennedy suggested farmers 'should consider maybe the possibility of letting it run through the flock so that we can identify the birds and preserve the birds that are immune to it.' This, as former Kansas state veterinarian Dr. Gail Hansen put it, is a 'terrible idea' and a 'recipe for disaster.'
Dr. Adalja did not mince words. If the past year has been a trial run for how the government might respond to the actual emergence of an avian flu pandemic, he says, 'we've failed this trial run.'
Optimistically, on a global level, the World Health Organization (WHO) has been taking positive steps toward international collaboration: WHO's Global Influenza Surveillance and Response System closely monitors avian and other animal influenza viruses, and in May, member states approved an agreement to better prevent, prepare for, and respond to outbreaks and learn from mistakes made at the height of the Covid pandemic.
But remember, the Trump-Vance Administration pulled the U.S. out of the WHO effective in 2026, and has revoked a variety of investments in global and domestic health programs. These decisions are not abstract, Dr. Adalja says: they 'make these types of events much harder to prepare for and much harder to control.'
As Covid-19 made abundantly clear, viruses don't stop at national borders. Keeping the public healthy and preparing for pandemic risks simply must be more important than politicking. And when we're heading in the wrong direction, there is a moral obligation to sound the alarm—and to illuminate a better path forward.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
First new treatment for advanced bladder cancer in decades given green light
A new treatment for advanced bladder cancer which doubles survival time has been given the green light for NHS use. Experts said the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease, saying that until now, the treatment for advanced bladder cancer had not significantly changed since the 1980s. They said there had been real 'unmet need' for patients with advanced disease, with some 29% of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30%) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5% of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.


CBS News
2 hours ago
- CBS News
Maryland researchers find that otter poop can tell important information about the ecosystem
Otters may look adorable, but scientists say their poop is a goldmine of information. A new study from the Smithsonian Environmental Research Center in Edgewater, Maryland, found that otter poop, or "scat," serves as a natural report card for the ecosystem. A team of scientists at the Smithsonian Environmental Research Center spent the past few years collecting and studying otter poop from these latrines along the Rhode River. Their study, published last week, found otter scat contains important clues about what's going on in our waterways. "As an apex predator and a disease sentinel, river otters can serve as a sort of an indicator of the health of the ecosystem and if things are or are not going well," said Calli Wise, the lead author of the study. By testing the droppings, researchers found that otters are eating fish and a lot of crustaceans, along with smaller mammals and birds, most importantly parasites. "The fact that river otters eat so many parasites is actually really important for the health of the ecosystem, and the people that rely on this ecosystem for a living." Wise says parasites help balance the food chain, and because otters live both on land and in water, the parasites in their prey can be an early warning system for environmental changes. "Seeing if that changes over time can be a flag, a signal to people when things are going well or poorly in the water," Wise said. Otters can even warn of potential risks to humans. "Those would be things that we'd look at as indicators of poor water quality or sewage or other things in the water column." The team hopes their findings will aid restoration efforts in the future. "It's been really fun to see otters popping up in more urban spaces and see people get excited about conservation related to this species."
Yahoo
2 hours ago
- Yahoo
'Dinosaur tree' produces seeds for first time
A rare pine tree dubbed the "dinosaur tree" because as a species it is millions of years old, has produced seeds for the first time, after being nurtured for a decade in the UK. The Wollemi pine is part of Pear Tree Garden in Wichenford, Worcestershire, and bore fruit in the form of male and female cones earlier this year. Pam Thompson and her husband planted the tree, unaware of how it may "grow, die or thrive" in their garden. The prehistoric tree, first discovered in Australia in 1994, is one of the rarest trees in the world and is potentially facing extinction. Mrs Thompson told the BBC she intends to share out the seeds of the cones in an effort to get the tree off the critically-endangered list. Mrs Thompson said: "I had been keeping half an eye on a female cone for ages as I was advised they usually drop their seeds in late August early September "This year has been so unusually dry, it happened earlier," she said. "I reached up to a female cone and the seeds all cascaded into my cupped hands as I touched it. "It was very exciting actually collecting the seeds from such an ancient tree that lived when dinosaurs roamed - I shall definitely try to germinate seeds from a critically endangered tree." Members of the public will be able to visit the tree at Pear Tree Garden on Sunday as part of the National Garden Scheme. Follow BBC Hereford & Worcester on BBC Sounds, Facebook, X and Instagram. More on this story Rare tree bearing fruit with hope of seedlings Related internet links Pear Tree Cottage Garden National Garden Scheme Solve the daily Crossword